Novartis may jettison some of its small businesses


CEO Joe Jimenez' review of the viability of Novartis' (NVS) small divisions will probably mean that at least one will eventually be sold.

Three units: animal health, vaccines and OTC medicines won't globally scale so it the best solution for shareholders may be to get rid of them.

He cites the unattractive reimbursement environment as the main challenge for the businesses.

From other sites
Comments (1)
  • SSnape
    , contributor
    Comments (614) | Send Message
     
    I would be really sorry to see NVS exit the animal health field.

     

    Long: NVS.
    20 Mar 2014, 02:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs